Beam Therapeutics Inc. (NasdaqGS:BEAM) announced that it has entered into a securities purchase agreement for the private placement of 2,795,700 common shares at an issue price of $93 per share for gross proceeds of $260,000,100 on January 16, 2021. The transaction will include participation from Perceptive Advisors LLC, Farallon Capital Management, L.L.C., Casdin Capital, LLC, returning investors Redmile Group, LLC, Cormorant Asset Management, LLC, and other investors. The closing of the transaction is anticipated to occur on January 21, 2021, subject to the satisfaction of customary closing conditions.